{
  "abstract": "Purpose: To evaluate the effect of resveratrol, quercetin, and curcumin (RQC) compared with curcumin alone on drusen volume and clinical outcomes in patients with age-related macular degeneration (AMD).\n\nMethods: In this open-label, randomized phase 2a clinical trial, patients with early and intermediate AMD were randomized 2:1 to oral RQC or curcumin for 24 months. The primary outcome was the mean change in central drusen volume from baseline measured using spectral-domain optical coherence tomography (SD-OCT). Secondary outcomes included analyses of drusen volume and number by baseline size, categorical analyses of individual drusen response, change in best-corrected visual acuity (BCVA), frequency of vision loss, progression to advanced AMD, and safety.\n\nResults: Thirty-eight patients were included in the final analysis. After 24 months, central drusen volume decreased significantly with RQC compared with curcumin (−13.4% vs. +6.9%; P = 0.02). Mean BCVA increased by 0.8 letters in the RQC group and decreased by 2.1 letters in the curcumin group (P = 0.08). The frequencies of both mild and moderate vision loss were lower in the RQC group. Progression to advanced AMD occurred in 3.7% of participants and 2.3% of eligible eyes in the RQC group.\n\nConclusions: RQC treatment was associated with reductions in drusen volume, low rates of progression to advanced AMD, and maintenance of BCVA over 24 months.\n\nTranslational Relevance: This study provides preliminary clinical evidence that this oral therapy may reduce drusen burden and warrants further evaluation as a potential treatment for early to intermediate AMD.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Ophthalmology and Visual Sciences, University of Illinois College of Medicine Chicago, Chicago, IL, USA",
    "Department of Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 2,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Nicholas M. Pfahler"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Paul A. Knepper"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/ek9z1shb392g2.bib",
  "cited_by": 0,
  "doi": "10.1167/tvst.15.10.50",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13722961/",
  "id": "ek9z1shb392g2",
  "issns": [
    "2164-2591"
  ],
  "landing_url": "https://doi.org/10.1167/tvst.15.10.50",
  "language": "en",
  "licence": "CC-BY-NC-ND-4.0",
  "licence_label": "CC BY-NC-ND 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Clinical Trials"
    ],
    [
      "openalex",
      "2731|Retinal Diseases and Treatments"
    ]
  ],
  "openalex": "W7224600748",
  "pdf_url": null,
  "pmcid": "PMC13722961",
  "pmid": "42954735",
  "published": "2026-10-29",
  "publisher": "Association for Research in Vision and Ophthalmology",
  "ris": "https://research.draconitic.com/paper/ek9z1shb392g2.ris",
  "sources": [
    {
      "first_seen": "2026-11-04T12:21:39Z",
      "native_id": "PMC13722961",
      "source": "pmc",
      "url": "https://doi.org/10.1167/tvst.15.10.50"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "heading:Clinical Trials",
      "subfield": "clinical-trials"
    }
  ],
  "title": "The Effect of Resveratrol, Quercetin, and Curcumin on Drusen Volume in Age-Related Macular Degeneration: A Randomized Clinical Trial",
  "title_text": "The Effect of Resveratrol, Quercetin, and Curcumin on Drusen Volume in Age-Related Macular Degeneration: A Randomized Clinical Trial",
  "type": "peer-reviewed",
  "updated_at": "2026-11-04T12:21:39Z",
  "url": "https://research.draconitic.com/paper/ek9z1shb392g2",
  "venue": "Translational Vision Science & Technology",
  "versions": []
}